KLRG1 and breast carcinoma: KLRG1 in LUAD and melanoma can serve as a marker for detecting the response to treatment with immune checkpoint inhibitors [16, 28] and has the potential to be a therapeutic target in breast cancer, melanoma, and CRC [8, 22, 116].